NCT03924245 2022-04-04Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube CancersVanderbilt-Ingram Cancer CenterPhase 1 Terminated3 enrolled